BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:fingolimod (Gilenya) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of fingolimod (Gilenya)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06424067-4672@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:fingolimod (Gilenya): Phase 2 readout est. (NCT06424067)
DESCRIPTION:fingolimod (Gilenya)\, phase 2.\nStudy: Phase 2 Study of Fingol
 imod in Lung Cancers\nEstimated primary completion: 1 May 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/fingolimod-gilenya#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06424067
URL:https://assetmemo.bio/drug/fingolimod-gilenya#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05285878-4672@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:fingolimod (Gilenya): Phase 2 readout est. (NCT05285878)
DESCRIPTION:fingolimod (Gilenya)\, phase 2.\nStudy: Fingolimod for the Abro
 gation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Trans
 plantation\nEstimated primary completion: June 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/fingolimod-gilenya#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05285878
URL:https://assetmemo.bio/drug/fingolimod-gilenya#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05307731-4672@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20280315
DTEND;VALUE=DATE:20280316
SUMMARY:fingolimod (Gilenya): Phase 4 readout est. (NCT05307731)
DESCRIPTION:fingolimod (Gilenya)\, phase 4.\nStudy: Fingolimod for Type 2 D
 iabetes Mellitus\nEstimated primary completion: 15 March 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/fingolimod-gilenya#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05307731
URL:https://assetmemo.bio/drug/fingolimod-gilenya#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220252-4672@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20300101
DTEND;VALUE=DATE:20300102
SUMMARY:fingolimod (Gilenya): Phase 2/3 readout est. (NCT07220252)
DESCRIPTION:fingolimod (Gilenya)\, phase 2/3\, Multiple Sclerosis.\nStudy: 
 Study to Assess Effects of Ublituximab in Pediatric Participants With Rela
 psing Forms of Multiple Sclerosis\nEstimated primary completion: 1 January
  2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/fingolimod-gil
 enya#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07220252
URL:https://assetmemo.bio/drug/fingolimod-gilenya#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07483632-4672@assetmemo.bio
DTSTAMP:20261121T005005Z
DTSTART;VALUE=DATE:20340728
DTEND;VALUE=DATE:20340729
SUMMARY:fingolimod (Gilenya): Phase 3 readout est. (NCT07483632)
DESCRIPTION:fingolimod (Gilenya)\, phase 3\, Multiple Sclerosis.\nStudy: A 
 Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl F
 umarate (DMF) and Their Effects on Relapses in Pediatric Participants With
  Relapsing Forms of Multiple Sclerosis (RMS)\nEstimated primary completion
 : 28 July 2034. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fingo
 limod-gilenya#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07483632
URL:https://assetmemo.bio/drug/fingolimod-gilenya#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
